Diagnosing Invasive Aspergillosis during Antifungal Therapy by PCR Analysis of Blood Samples
- 1 September 2004
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (9) , 4154-7
Abstract
We evaluated the value of Aspergillus PCR as a tool for diagnosing invasive aspergillosis from whole-blood samples during antifungal therapy. In a 3-year study, 36 patients receiving antifungal therapy due to chest radiographic findings highly suggestive of fungal pneumonia were evaluated. The PCR results from whole-blood samples were compared to those obtained from bronchoalveolar lavage fluids and/or tissue specimens. A total of 205 whole-blood samples, 15 fine-needle aspirations or tissue biopsy specimens, and 21 bronchoalveolar lavage fluids and tracheal secretions were analyzed using PCR. Of the 36 patients, 15 had proven, 9 had probable, and 12 had possible invasive Aspergillus infection according to European Organization for Research and Treatment of Cancer/Mycosis Study Group definitions. For patients with proven infection the sensitivity values of PCR in lung and blood samples were 100 and 40%, respectively. The negative predictive value of blood monitoring under conditions of antifungal treatment was 44%. Clearance of fungal DNA from blood was associated with resolution of clinical symptoms in six of nine patients with proven infection. Repeated positive PCR results for Aspergillus were associated with fatal outcome, as three of six patients died. For patients with probable infection the sensitivity values of PCR in lung fluid and blood were 66 and 44%, respectively. The benefit of PCR diagnosis using whole-blood samples is limited when sampling takes place after treatment has been started. Performance of Aspergillus PCR using tissue samples is recommended in addition to microscopic examination and culture technique for sensitive detection of fungal infection.Keywords
This publication has 26 references indexed in Scilit:
- Prospective clinical evaluation of a LightCyclerTM‐mediated polymerase chain reaction assay, a nested‐PCR assay and a galactomannan enzyme‐linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipientsBritish Journal of Haematology, 2004
- Use of Circulating Galactomannan Screening for Early Diagnosis of Invasive Aspergillosis in Allogeneic Stem Cell Transplant RecipientsThe Journal of Infectious Diseases, 2002
- Polymerase Chain Reaction Detection ofAspergillusDNA in Experimental Models of Invasive AspergillosisThe Journal of Infectious Diseases, 2002
- AspergillusGalactomannan Detection in the Diagnosis of Invasive Aspergillosis in Cancer PatientsJournal of Clinical Oncology, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002
- Aspergillus Fungemia: Report of Two Cases and ReviewClinical Infectious Diseases, 1995
- Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearanceClinical and Experimental Immunology, 1992
- Opportunistic Mycoses in the Immunocompromised Host: Experience at a Cancer Center and ReviewClinical Infectious Diseases, 1992
- Pulmonary Aspergillosis in the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1991
- Treatment of Invasive Aspergillosis: Relation of Early Diagnosis and Treatment to ResponseAnnals of Internal Medicine, 1977